Twist Bioscience Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
15.0%projected annual EPS growth
Analyst Coverage
10analysts covering
FY Revenue (est.)
$456.3Mnext fiscal year
FY EPS (est.)
-$0.60next fiscal year
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly110.7MTarget: 442000000 to 447000000
Gross Margin Quarterly5,160.0%Target: Above 52%
Adjusted EBITDA Quarterly-13.3MTarget: Breakeven
Watch Items
- Adjusted EBITDA Breakeven TargetTrigger: Failure to achieve breakeven by Q4 Fiscal 2026Action: Re-evaluate cost structure, operational efficiency, and headcount allocation.
- AI-Enabled Drug Discovery DemandTrigger: Therapeutics segment revenue growth slowing below 30% YoYAction: Assess wet lab capacity, partnership pipelines, and AWS Bio Discovery integration.
Research as of 20 Jun 2026